Summa Equity acquires HyTest

The investment in HyTest is Summa's first in the Finnish market. The GP is currently investing from Summa Equity Fund I, a SEK 4.5bn buyout fund that held a final close in February 2017 and was 50% deployed by March 2018. The vehicle had made seven investments as of March, four of which were in Sweden, two in Norway and one in Poland, according to Unquote Data.

Following completion of the transaction Summa Equity will be the majority shareholder in HyTest, and the founders and management team will remain as significant shareholders in the company.

Company
Founded in 1994 and headquartered in Turku, HyTest produces antibodies and antigens for the diagnostics industry. The company was founded by a group of scientists who are still members of senior management. It employs a staff of around 100 people.

HyTest's customer base includes a number of companies that supply in vitro diagnostic devices, active across the US, Asia and Europe.

People
Summa Equity – Tommi Unkuri (partner).
HyTest – Maria Severina (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Nordics
• Healthcare
• Finland